These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8072437)

  • 1. Estrogens and Parkinson's disease.
    Session DR; Pearlstone MM; Jewelewicz R; Kelly AC
    Med Hypotheses; 1994 Apr; 42(4):280-2. PubMed ID: 8072437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a connection between estrogen and Parkinson's disease?
    Shulman LM
    Parkinsonism Relat Disord; 2002 Jun; 8(5):289-95. PubMed ID: 15177058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender disparities in Parkinson's disease.
    Shulman LM; Bhat V
    Expert Rev Neurother; 2006 Mar; 6(3):407-16. PubMed ID: 16533144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
    Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
    Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Menstrual-related fluctuations in Parkinson's disease.
    Quinn NP; Marsden CD
    Mov Disord; 1986; 1(1):85-7. PubMed ID: 3504235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain.
    Schlaff WD; Carson SA; Luciano A; Ross D; Bergqvist A
    Fertil Steril; 2006 Feb; 85(2):314-25. PubMed ID: 16595206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen and Parkinson's disease.
    Kompoliti K
    Front Biosci; 2003 May; 8():s391-400. PubMed ID: 12700049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk.
    Spicer DV; Ursin G; Parisky YR; Pearce JG; Shoupe D; Pike A; Pike MC
    J Natl Cancer Inst; 1994 Mar; 86(6):431-6. PubMed ID: 8120917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential sensitivity of estrogen target tissues: implications for estrogen regulation of serum luteinizing hormone.
    Kelner KL; Peck EJ
    J Neurosci Res; 1984; 11(1):79-89. PubMed ID: 6708135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson's disease.
    Dluzen DE; McDermott JL
    J Gend Specif Med; 2000; 3(6):36-42. PubMed ID: 11253381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Menstrual-related changes in motoric function in women with Parkinson's disease.
    Kompoliti K; Comella CL; Jaglin JA; Leurgans S; Raman R; Goetz CG
    Neurology; 2000 Nov; 55(10):1572-5. PubMed ID: 11094119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen and Parkinson's disease.
    Horstink MW; Strijks E; Dluzen DE
    Adv Neurol; 2003; 91():107-14. PubMed ID: 12442669
    [No Abstract]   [Full Text] [Related]  

  • 14. Menopause and Parkinson's disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration.
    Labandeira-Garcia JL; Rodriguez-Perez AI; Valenzuela R; Costa-Besada MA; Guerra MJ
    Front Neuroendocrinol; 2016 Oct; 43():44-59. PubMed ID: 27693730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The adverse effects of hormonal therapy.
    Bush TL
    Cardiol Clin; 1986 Feb; 4(1):145-52. PubMed ID: 3518931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects of leuprolide acetate depot treatment.
    Friedman AJ; Juneau-Norcross M; Rein MS
    Fertil Steril; 1993 Feb; 59(2):448-50. PubMed ID: 8425646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of p38 pathway-dependent MPTP-induced dopaminergic neurodegeneration in estrogen receptor alpha knockout mice.
    Hwang CJ; Choi DY; Jung YY; Lee YJ; Yun JS; Oh KW; Han SB; Oh S; Park MH; Hong JT
    Horm Behav; 2016 Apr; 80():19-29. PubMed ID: 26836768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system.
    Gao X; Dluzen DE
    Neuroscience; 2001; 103(2):385-94. PubMed ID: 11246153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunosuppressive aspects of estrogen].
    Ciesielska A
    Neurol Neurochir Pol; 2003; 37 Suppl 3():79-92. PubMed ID: 14560702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen and SERM neuroprotection in animal models of Parkinson's disease.
    Morissette M; Al Sweidi S; Callier S; Di Paolo T
    Mol Cell Endocrinol; 2008 Aug; 290(1-2):60-9. PubMed ID: 18515001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.